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Epigenetic changes in multiple genes are emerging as an important mechanism for tumour
cells to acquire resistance to chemotherapy. In the present work, we test the hypothesis
that epigenetic organisation in cancer cells can be affected by cytostatic drugs. Colorectal
cancer cells were cultured for several weeks in the presence of 6-thioguanine. Bisulphite
sequencing of the CpG-rich promoter regions of two expressed genes showed a signifi-
cantly increased frequency of methylated CpG sites in drug-treated cells, as compared with
controls: 4.7% and 1.7%, respectively, for the HPRT gene; and 11.1% and 8.2% for CDX1.
Essentially, all of the increase for the CDX1 gene was in a four CpG sub-region previously
found to correlate with gene activity (P = 0.006). This pattern of sparse promoter methyla-
tion fits with a recently proposed ‘seeding’ two-step mechanism leading up to gene inacti-
vation in cancer cells. Taken together, our findings suggest activation in cancer cells of an
epigenetic process enabling a tumour to generate drug-resistant variant cells.
 2006 Elsevier Ltd. Open access under CC BY-NC-ND license.1. Introduction
Resistance to cancer chemotherapy can bemediated by muta-
tions in specific genes such as MDR1 (P-glykoprotein).1 This
has been well documented in cells in vitro and in transgenic
mice. Nevertheless in a clinical setting neither the status of
MDR1 or any other so far identified individual gene has served
as a useful predictor of therapy response (reviewed in Ref. [2]).
The contribution of epigenetic changes to treatment failure
has, however, been reported recently, including CpG methyla-
tion of the hMLH1 promoter in ovarian cancer occurring dur-
ing development of drug resistance. This has even been
reported to become detectable as free tumour DNA circulating
in patient sera.3 At very high drug levels (typically giving >95%
cell kill and DNA synthesis inhibition) the changes in overall
DNA methylation have been documented, with some drug
types causing hypermethylation, for example carboplatin.; fax: +44 1865 222431.
ox.ac.uk (W. Bodmer).
C BY-NC-ND license.When a lung cancer cell line was exposed to 6-thioguanine
(6TG) at 100 lM there was a decrease in the total DNA content
of methylated bases, but there was no effect at 10 lM.4 There
are also data suggesting that an interplay between epigenetic
changes in multiple genes is needed for a tumour to acquire
resistance.5,6 However, an unresolved issue is whether resis-
tant cells are present as rare epigenetic variants already at
the start of treatment, eventually to become enriched by
selection, or whether in sensitive cells epigenetic regulatory
mechanisms can be affected by a cytostatic drug stress. It
has been known for some time that environmental stress
factors are associated with epigenetic changes. In plants,
chemical mutagens and cold can lead to epigenetic modi-
fication.7,8 Such observations have also been made in
mammals. Tumours induced in rodents by exposure to chem-
ical carcinogens have been found to contain not only
oncogene mutations, but also epigenetically silenced tumour
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ted with nickel or DNA alkylating agents develop cancer-
related epigenetic changes.10–12
In the present work, we attempt to answer the question
as to whether tumour cells respond to clinically attained
chemotherapy levels with epigenetic modifications. If that
is the case then this may help in designing strategies to
combat an important source of therapy failure. Colorectal
cancer (CRC) cell lines were exposed to relatively low levels
of 6-thioguanine (6TG), a drug in clinical use, allowing some
growth to continue for several weeks. Bisulphite sequencing
of the promoter regions of two genes was then carried out.
The first gene, HPRT, is involved in cellular resistance to this
drug, as it is essential for 6TG to become incorporated into
DNA in order to exert its cytostatic effect, and the second
gene, CDX1, has no known functional relationship to the ef-
fects of 6TG.
2. Materials and methods
2.1. Cells and 6TG treatment
Mononuclear cells were separated from freshly collected ve-
nous blood from healthy donors by Lymphoprep (Axis-Shield,
Oslo, Norway) gradients and used directly. The T84 andFig. 1 – Sequences of the 5 0-flanking regions for human and mo
assuming all CpG sites are unmethylated. CpG’s are underlined.
bold. Positions relative to the human exon 1 start are shown ab
positions.SW620 CRC cell lines both originate from male patients. They
have both been shown to be hMLH1-positive, suggesting
normal DNA mismatch repair function. The CRC lines were
cultured under standard conditions with 10% (v/v) bovine ser-
um in the medium, and split as appropriate before confluence
was reached. 6TG was from Sigma (A4882), and a stock solu-
tion of 10 mM in 0.2 M NaOH was prepared and kept in ali-
quots at 20 C. The cultures were washed and fresh
medium with 6TG added at least once per week, in order to
maintain the desired 6TG concentration. The CFDA (carboxy-
fluorescein diacetate) fluorescent dye exclusion test was used
to determine cell viability, as described previously.13
2.2. Bisulphite sequencing
DNA was extracted from the cells using the DNeasy kit
(Qiagen, Crawley, UK). DNA (0.5 lg) was bisulphite-modified
using the EZ DNA Methylation-Gold Kit, as recommended by
the manufacturer (Zymo Research, Orange, CA). A promoter
region was amplified by PCR as described below, and the
PCR product was purified from a solubilised agarose gel slice
using a silica column (Qiagen), cloned (TopoTA cloning kit,
Invitrogen, Purchase, NY), and finally submitted to the local
sequencing core facility for ABI sequencing (Applied
Biosystems).use HPRT. The bisulphite-modified sequence is human DNA,
Mouse portions homologous to the human sequence are in
ove the bisulphite line. The arrows indicate the PCR primer
Table 1 – Sensitivity of CRC cell lines to 6TG
CRC 6TG
(lM)
Total cell number,
relative to absence of 6TG (% dead cells)
7
days 6TG
17
days 6TG
T84 0 100 (7) 100 (3)
1 60 (10) 67 (4)
2 22 (11) 13 (3)
4 4 (11) 8 (7)
8 2 (9) 1 (5)
16 1 (14) <1 (6)
SW620 0 100 (1) n.d.
1 25 (2) n.d.
2 14 (1) n.d.
4 2 (2) n.d.
8 1 (1) n.d.
16 <1 (2) n.d.
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PCR primers were designed based on the HPRT and CDX1 5 0-
flanking regions given on the University of California at Santa
Cruz website http://genome.ucsc.edu. For the sequencing PCR
reaction the primers bind to non-CpG sequences in order to
yield products irrespective of the template’s CpG methylation
status (positions indicated in Fig. 1). The forward primer was
5 0-ATTGAGTTGGGAGGGAAAGG, and the reverse primer was
5 0-CCATTTCCACCTTCTCTTCCCA. Cycling conditions were
95 C for 12 min followed by 40 cycles of 95 C 1 min, 58 C
1 min 30 s, 72 C 2 min 30 s, and then finally 72 C for
10 min. The 25 ll reaction solution contained 0.2 lM each pri-
mer, 0.1 U Hotstar Taq polymerase (Qiagen), 1.5 mM MgCl2,
200 lM each dNTP and 2 ll of the bisulphite-modified DNA.
The PCR products were visualised after gel electrophoresis
through 1.5% (w/v) agarose containing ethidium bromide.
The primer positions for the HPRT methylation-specific PCR
are also shown in Fig. 1. These primers were designed to bind
to DNA methylated at several CpG sites: the forward primer
was 5 0-AATTGGTAGGCGTCGGCGTAGGCGCGC, and the re-
verse primer was 5 0-CCGACAAACCGAACTACTCACCACGAC.
The cycling conditions were similar to those for the HPRT
sequencing PCR, with the following differences: annealing
at 63 C, elongation for 1 min 30 s. For CDX1 sequencing PCR
was performed as describer earlier.14 For all PCR reactions,
only the bisulphite-modified sense strand was amplified,
starting with the reverse primer binding to this sense strand,
and the complementary molecule thus produced serving as a
template for the forward primer.
2.4. Statistical analysis
The significance of all the 2 · 2 comparisons was assessed
using Fisher’s exact test.
3. Results
3.1. Definition of 6TG concentrations used for long-term
treatment of CRC cell lines
The T84 and SW620 CRC cell lines were kept in medium con-
taining up to 16 lM 6TG, and split as needed to keep the cul-
tures proliferating at 20–80% confluence. In patients, plasma
concentrations of up to 10 lM 6TG have been documented
for the Lanvis pharmaceutical preparation (RxMed website
http://www.rxmed.com). Expression of the HPRT gene in both
lines was confirmed by RT-PCR, and there was no apparent
change in the level of expression following 6TG treatment (re-
sults not shown). Total cell number and the fraction of dead
cells, as determined by the fluorescent dye exclusion test,
were analysed after 1 week of culture (Table 1). No growth
was seen at the highest concentrations of 6TG (8–16 lM),
whereas sustained strong growth was seen at 1 lM 6TG, with
both T84 and SW620 reaching 25–60% of the total cell number
achieved by the untreated controls. T84 had a slightly higher
growth rate than SW620, and there was no apparent effect of
6TG on cell death for either of the two cell lines. Paradoxically,
the more marked growth retardation of SW620 in 6TG was
coupled with less death. A similar sensitivity to 6TG was alsoseen with other CRC lines (COLO201, COLO678 and SW1116;
results not shown). Based on these findings, 1 lM 6TG was
considered to provide an optimal level of cytostatic drug
stress on the CRC lines during long-term culture. T84 was still
proliferating after one month in 1 lM 6TG (see T84 data at 17
days in Table 1). A minor reduction of the growth rate was
also seen at 0.25 lM 6TG for SW620 (results not shown). For
all long-term experiments, a 16 lM 6TG culture was set up,
in addition to cultures at 0 and 1 lM. Only a few cells were
occasionally detectable after one month of culture. This
suggests that cells harvested from cultures maintained for
several weeks in low concentrations of 6TG do not signifi-
cantly represent outgrowth of rare variants with a complete
lack of HPRT expression likely to be present at the start of
the culture. Such variants are expected to occur at a fre-
quency of approximately 106 in CRC lines,15 while for the
cloning of HPRT-mutants much higher 6TG concentrations,
namely around 10–15 lM, are usually used.16
3.2. Analysis of CpG methylation in the HPRT promoter
region
The HPRT gene has been extensively studied.17–19 There is a
very good evidence indicating that its expression is regulated
by a CpG-rich approximately 500 bp upstream region. Due to
the X chromosome location of HPRT, and its house-keeping
function in the nucleotide salvage pathway, human cells in
general carry only a single active allele. However, which CpGs
are most important for the control of HPRT gene expression
has not been clearly established. In the present work, we have
chosen to study the 357 bp region 5 0 to exon 1 because of its
relatively high homology with the corresponding mouse se-
quence (61%, as compared to 34% in the further upstream
250 bp) (Fig. 1). This 357 bp segment contains a total of 43
CpG sites, and several transcription factor-binding motifs
including, for example, four GGGCGG Sp1 sites. After DNA
extraction and bisulphite-modification, the promoter region
was PCR-amplified, cloned and sequenced. In accordance
with published data,19 the promoter in male lymphocytes
was virtually free from methylated CpGs, whereas clones
with dense methylation were found in female lymphocytes
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(all six clones were hyper-methylated) indicates that bisulph-
ite-modified molecules containing relatively few long thy-
mine-rich stretches (due to the conversion by bisulphite of
cytosine to thymine, while methylated cytosines remain as
cytosine) are preferentially amplified by the current PCR pro-
tocol. T84 cells, originating from a tumour of a male patient,
showed a very low level of methylation (Fig. 2b, upper panel),
similar to that in male lymphocytes. T84 cells exposed for 28
days to 6TG showed no signs of the heavy methylation found
in female lymphocytes (Fig. 2b, lower panel). However, the to-
tal number of methylated CpGs among the total of 12 clones
analysed from the 6TG-treated cultures (4.7%) was signifi-
cantly higher than that in the 11 clones from the untreated
cells (1.7%). These results are given in Table 2, together withFig. 2 – HPRT promoter bisulphite DNA sequencing results
for individual CpG sites: (a) seven clones from male lym-
phocytes and six from female lymphocytes and (b) 11 clones
from untreated T84 cells and 12 from 6TG-treated T84. Each
of the 43 CpG sites is shown as a circle, and methylated
CpGs are highlighted in black. The base positions relative to
the exon 1 start site are shown. Each line represents one
clone.an estimate of the possible artefactual contribution to the
scoring of methylated CpGs arising from bisulphite-modifica-
tion errors. In the analysed 376 bp HPRT promoter region
there is a total of 88 cytosines at non-CpG positions, all of
which are assumed to be unmethylated, and therefore should
be converted to thymines by bisulphite. The number of cyto-
sines remaining after bisulphite-modification at these 88
positions can be used as a measure of the bisulphite failure
rate assuming that this is the same for C at CpG and non-
CpG sites. Thus, for example, the 1.5% of errors for 6TG un-
treated T84 suggests that the observed figure of 1.7% of C’s
at CpG sites mainly reflects bisulphite modification failures,
whereas for the 6TG-treated T84 cells subtraction of the
2.1% errors from the 4.7% of observed cytosines at CpG sites
indicates a true presence of 2.6% methylated CpG sites, the
difference presumably being due to the effects of culturing
in the presence of low concentrations of 6TG. There was no
significant change in the numbers of methylated C sites at
the non-CpG positions. Line SW620 showed a slightly lower
increase in the number of methylated C sites at CpG posi-
tions, but this was not significant because fewer clones were
analysed.
3.3. Analysis of CpG methylation in the CDX1 5 0-flanking
region
CDX1 is involved in colonic epithelium differentiation and
was chosen as a representative gene with no known specific
role in 6TG toxicity. In a previous report on a panel of 37
CRC lines, we found evidence for a role for CDX1 as tumour
suppressor in colorectal cancer,14 with 12 of the analysed
lines showing either CDX1 silencing due to promoter methyl-
ation or a pattern of partial methylation. We now find lym-
phocytes to have heavy CDX1 promoter methylation, in
accordance with our previous result for a lymphoblastoid cell
line, suggesting, as expected, that CDX1 is not expressed in
these cells (Fig. 3a). In our earlier study, T84 was positive for
CDX1 mRNA and showed no signs of heavy promoter methyl-
ation as judged by methylation-specific PCR. In line with
these published data, we now see a sparse CDX1 promoter
methylation among the 15 analysed T84 clones grown in the
absence of 6TG. There is, in particular, very little methylation
at the four CpG sites shown to be strongly correlated with
gene expression14 (Fig. 3b, upper panel). Interestingly, how-
ever, the region containing the 29 CpGs before the four CpG
sites differs significantly in the proportion of CpG sites with
methylated C versus that containing the five CpG sites after,
and neither show any significant change with growth in 6TG
(including control and 6TG data, 7.2% versus 18%, P = 0.001).
T84 cells exposed to 6TG for 28 days showed a slightly higher
overall proportion of methylated CpGs, similar to the results
for HPRT, with an increase from a relatively high basal level
of 8.2–11.1% in the 6TG-treated culture (Fig. 3b, lower panel,
and Table 3). However, essentially all of the increase was in
the four CpG sub-region previously found to correlate with
gene expression (marked with a box in Fig. 3), where the
change from 7% to 27% was highly significant with a P-value
of 0.006, which remains significant even allowing for the
selection made of the four CpG box sequence for which the
comparisons were done. The bisulphite modification errors
Table 2 – HPRT promoter: bisulphite DNA sequencing results
Cells Number of
sequenced clones
6TG (lM/days) C at CpG sites
(=methylated CpG)
C at non-CpG site
(=bisulphite failure)
Male lymphocytes 7 0 0 4/301 (1.3%) 6/616 (1.0%)
Female lymphocytes 6 0 168/258 (65.1%) 21/528 (4.0%)
T84 11 0 8/473 ( 1.7%) 15/968 (1.5%)
T84 12 1/28 d 24/516 (4.7%)a 22/1056 (2.1%)b
SW620 2 0 0/86 (<1.2%) 0/176 (<0.6%)
SW620 2 0.25/7 d 0/86 (<1.2%) 0/176 (<0.6%)
SW620 5 1/7 d 4/215 (1.9%)c 1/440 (0.2%)
All significance tested by Fisher’s exact test, two sided (except where indicated), results as P-values.
a Control versus 6TG, P = 0.0108.
b NS.
c Control and 0.25 6TG versus 1 6TG, P = 0.1323 (one sided p = 0.0941).
Fig. 3 – CDX1 promoter bisulphite DNA sequencing results for individual CpG sites: (a) six clones from lymphocytes and (b) 15
clones from untreated and 6TG-treated T84 cells, respectively. Each of the 38 CpG sites is shown as a circle, and methylated
CpGs are highlighted in black. The base positions relative to the transcription start site are shown. The box denotes the four
CpG sites correlating strongly with gene expression.14 Each line represents one clone.
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Table 3 – CDX1 promoter: bisulphite DNA sequencing results
Cells Number of
sequenced clones
6TG (lM/days) C at CpG sites
(=methylated CpG)
C at non-CpG
site (=bisulphite failure)
Female lymph 6 0 162/228 (77.1%) 14/702 (2.0%)
T84 15 0 47/570 (8.2%) 44/1755 (2.5%)
T84 15 1/28 d 63/570 (11.1%)a 53/1755 (3.0%)b
All significance by Fisher’s exact test, two sided except where indicated, P-values given.
a P = 0.1321 (one sided 0.0661).
b NS.
Fig. 4 – No evidence for clones with high-density HPRT promoter methylation in 6TG-treated T84. Methylation-specific PCR
was performed with primers binding only to the methylated CpG stretches (as shown in Fig. 1). Bisulphite-modified DNA was
from female lymphocytes (lane 2), T84 without 6TG treatment (lane 3), T84 after 4 weeks with 1 lM 6TG (lane 4), male
lymphocytes spiked with a 100· dilution of the female lymphocyte DNA solution used in lane 2 (lane 5) (a faint band could be
seen in the illuminated gel), male lymphocytes as in lane 5 with no spiking (lane 6). Lane 1: female lymphocyte native DNA
not modified with bisulphite. W, water control; M, size marker.
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experiments (2.5% and 3.0%, respectively).
3.4. Methylation-specific PCR in search of rare heavy
promoter methylation events
Although sequencing revealed no signs of cells with a densely
methylated HPRT promoter suggestive of gene silencing, a low
frequency of such variants could not be excluded. Recently
two groups have, for example, presented evidence for a ‘seed-
ing’ two-step mechanism operating during tumour suppres-
sor gene silencing.20–23 The first step is suggested to involve
a low-density methylation occurring in a high fraction of
the tumour population, similar to that we have observed for
both HPRT and CDX1, while the second step involving high-
density promoter methylation leads to gene inactivation seen
only in a low fraction of the ‘seeded’ cells, presumably as a re-
sult of the selection for reduced gene expression. Stimulated
by these reports, we performed methylation-specific PCR,
using primers binding only to methylated CpG stretches. This
assay was sensitive enough to detect as little as one methyl-
ated copy among 100 unmethylated molecules (Fig. 4, lane
5). However, no PCR band was seen with the same 6TG-trea-
ted T84 cells that were used in Figs. 2 and 3, suggesting that
the frequency of T84 cells becoming heavily methylated dur-
ing 6TG treatment was less than 1% (Fig. 4).4. Discussion
We report here a significant, though low-level, increase in
promoter CpG methylation in colorectal cancer cells treated
with a cytostatic drug, 6TG, at a clinically relevant concentra-
tion. The data, which show variability in methylation within
the promoter regions of two genes both in controls and fol-
lowing 6TG treatment, indicate the potential complexity of
factors controlling DNA methylation at CpG sites. In addition
to the fact that the observed sparse methylation was statisti-
cally significant for both of the studied genes, a case can be
made in support of the relevance of our observations. The
determination of cytosine methylation at CpG sites is based
on the conversion of non-methylated cytosines to thymine,
whereas a 5 0-methylated cytosine is resistant, resulting in a
cytosine rather than thymine on sequencing analysis of bisul-
phite-modified DNA. Since cytosines located at non-CpG posi-
tions are considered not to become methylated, it is possible
to estimate the error rate of the bisulphite process by scoring
the number of cytosines remaining as a cytosine at non-CpG
sites. For the HPRT promoter in untreated T84 cells, the fre-
quency of such methodological errors was no different from
the frequency of methylation observed at CpG sites (1.5%
and 1.7%, respectively). Assuming a uniform error rate at all
cytosine positions, the true frequencies of CpG methylation
in T84 cells are therefore 1.7–1.5 = 0.2% for no 6TG and
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during 6TG treatment CpG methylation went from a virtually
methylation-free state (0.2%) to a sparsely methylated level of
2.6%. Superficially, the corresponding picture for the CDX1
gene was not as clear-cut, with a true basal CpG methylation
frequency of 8.2–2.5 = 5.7%, going up to 11.1–3.0 = 8.1% in 6TG-
treated T84 cells. However, this overall analysis hides the fact
that essentially all the change in the frequency of methyla-
tion occurred in the region of four CpGs (from 7% to 27% in
that region), which has been shown to be critical for the con-
trol of expression of the CDX1 gene.14 Thus, among the total
excess of 16 methylated CpG’s in 6TG-treated cells, 12 (75%)
occurred in a region representing only 11% (4/38) of the total
analysed CpG content.
If, as we believe our data show, there is a real, though low-
level drug-associated increase in promoter methylation, does
this represent a toxic and non-specific effect, or does it in any
way relate to the inactivation of tumour suppressor genes in
cancer? As already discussed, it has been suggested that
‘seeds of methylation’ may be an important precursor to
dense methylation.23 Thus, CpG silencing of a glutathione-
S-transferase (GSTP1) construct in prostate cancer cells has
been shown to require treatment with HpaIImethylase, medi-
ating sparse methylation.20 Similar data come from gastric
cancer cell lines where low-density methylation in most cells,
as we have found in 6TG-treated cells, was associated with
dense methylation in a small fraction of the cells for all the
five analysed genes including E-cadherin.22 These reports sup-
port that our findings of sparse methylation may reflect a
mechanism which provides the basis for an increased fre-
quency of gene silencing in cancer cells during anti-cancer
treatment, presumably following the selection for reduced
gene expression. Our findings are also in agreement with pre-
vious reports on the cumulative influence of epigenetic
changes in multiple genes for emergence of drug resistance,
on the assumption that drugs other than 6TG may act in a
similar way to increase methylation at CpG sites.5,6 It may
be speculated that besides HPRT and CDX1, a number of other
CpG island-containing loci in tumour cells exposed to cyto-
static therapy stress may acquire a concordant low-level
methylation.
Although our findings cannot exclude that variants with a
subtle reduction in HPRT expression or with some other resis-
tance mechanism were enriched for, it seems unlikely for at
least three reasons that the CpG methylation seen in our
HPRT promoter clones represents the outgrowth of a rare sub-
population of cells already present before 6TG treatment.
Firstly, there is no reason to assume that such a sparse pro-
moter methylation would in any way affect gene expression
or yield a selectable phenotype. This agrees with the cited re-
port on gastric cancer cell lines, showing no correlation be-
tween the fraction of methylation-seeded cells and the level
of gene expression,22 and also with our results on the level
of HPRT expression after growth in 6TG. Secondly, there was
a continuous increase in cell number at the 6TG concentra-
tion (1 lM) used by us, which argues against significant
enrichment of preformed variants. Thirdly, a 16 lM 6TG cul-
ture (a growth-inhibitory concentration used for the selection
of HPRT-negative cell clones) was always run in parallel with
the 1 lM culture. A steady decrease in cell number was thenobserved, with outgrowth of clones occurring in only a small
minority of all culture flasks.
In conclusion, our data show that treatment with low lev-
els of the cytotoxic drug 6TG leads to low-level increases of
methylation at CpG sites, which suggests that this may also
be seen with other drug treatments. In that case, such drug
treatments may be analogous to treatments which increase
the mutation rate, in that increasing the level of non-specific
CpG methylation may increase the probability of functionally
relevant methylation changes occurring, which are then se-
lected for. Future work is needed to document promoter
methylation in association with other treatment modalities
such as ionising radiation and alkylating agents, as well as
to test whether inhibition of CpG methylation may interfere
with the development of drug resistance.
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